The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States

Clinical Infectious Diseases

Volumn 63, Issue 8, 2016, Pages 1049-1055

  Klevens, R Monina ^a   Canary, Lauren ^a   Huang, Xiaohua ^b   Denniston, Maxine M ^a   Yeo, Anthony E ^b   Pesano, Rick L ^b   Ward, John W ^a   Holmberg, Scott ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Epidemiology; Fibrosis; Hepatitis C virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; AGE; ANALYTICAL PARAMETERS; ANTIVIRAL THERAPY; APRI SCORE; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FIBROSIS 4 SCORE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY ANALYZER; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTE COUNT; UNITED STATES; ADOLESCENT; AGED; COMPLICATION; COST OF ILLNESS; GENETICS; HEALTH SURVEY; HEPACIVIRUS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COST OF ILLNESS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; SEVERITY OF ILLNESS INDEX; UNITED STATES; YOUNG ADULT;

EID: 84990949341     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw468     Document Type: Article

References (21)

1. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The growing burden of mortality associated with viral hepatitis in the United States, 1999-2007. Ann Intern Med 2012; 156:271-8.
2. Mahajan R, Xing J, Liu S, et al. Mortality among people in care with hepatitis C virus infection-the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis 2014; 58:1055-61.
3. Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis 2014; 58:40-9.
4. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015; 61:157-68.
5. Smith BR, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. Morbid Mortal Weekly Rep 2012; 61(RR-04):1-18.
6. United States Preventive Services Task Force. Final Recommendation Statement: Hepatitis C: Screening, June 2013. Available at: http://www.uspreventive servicestaskforce.org/Page/Document/RecommendationStatementFinal/hepatitisc-screening. Accessed 8 August 2015.
7. American Association for the Study of Liver Disease and the Infectious Disease Society of American. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://www.hcvguidelines.org/. Accessed 8 August 2015.
8. Xu F, Moorman AC, Tong X, et al. All cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus. Clin Infect Dis 2016; 62:289-97.
9. Butt AA, Yan P, Lo Re V III, et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015; 175:178-85.
10. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32-6.
11. Holmberg SD, Lu M, Rupp LB, et al. Noninvasive serum markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis 2013; 57:240-6.
12. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015; 385: 1124-35.
13. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015; 62:1353-63.
14. Xu F, Leidner AJ, Tong X, Holmberg SD. Estimating the number of patients with chronic hepatitis C virus meeting 'highest' or 'high' priority treatment criteria in the United States. Am J Public Health 2015; 105:1285-9.
15. Canary L, Holmberg SD, Klevens RM. Limited access to new hepatitis C treatment under Medicaid. Ann Intern Med 2015; 163:226-8.
16. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015; 61:1860-9.
17. Mitruka K, Thornton K, Cusick S, et al. Centers for Disease Control and Prevention. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model-Arizona and Utah, 2012-2014. MMWR Morb Mortal Wkly Rep 2014; 63:393-8.
18. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509-16.
19. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med 2010; 153:231-9.
20. Udompap P, Mannalithara A, Heo N, Kim D, Ray Kim W. Increasing prevalence of cirrhosis among US adults aware or unaware of their chronic hepatitis C virus infection. J Hepatol 2016; 64:1027-32.
21. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011; 43:66-72.